Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review

• DOI: 10.3389/fonc.2021.796270
• Publication Date: 2022-01-21T08:56:23Z
• Authors: Vivek S. Radhakri...; Rajat Bajaj; Vasundhara Raina; Jeevan Kumar; Saurabh J. Bhave; Reghu K. Sukumara...; Arijit Nag; Indu Arun; Lateef Zameer; Debdeep Dey; Neeraj Arora; Mayur Parihar; Jayanta Das; Rimpa B. Achari; Deepak K. Mishra; Mammen Chandy; Reena Nair
• Keywords: Brentuximab vedotin; Bendamustine; Salvage therapy

Despite high cure rates with standard treatment, 30% patients Hodgkin lymphoma develop relapsed or refractory (R/R) disease. Salvage therapy followed by autologous hematopoietic cell transplantation (HCT) is considered of care. Brentuximab Vedotin (Bv) in combination Bendamustine (B) has been tested the salvage setting promising results.We conducted a single centre retrospective chart review who received BBv to determine its activity and safety R/R classical (HL). Between May 2011- December 2019, 179 were diagnosed HL.Thirty [median age: 30 (15-59) years, females (n=15)]. Primary disease 19 (63%), 26 (87%) had advanced stage at treatment. Most after 2 prior lines [n=16 (53%)]. The median number cycles 3 (1-6). delivered as outpatient was 63%. most common Grade III/IV hematological adverse event neutropenia [n=21, (70%)], while grade non-hematological toxicities included infections 4 (13%), neuropathy 4(13%), skin rash (7%), GI (10%) liver dysfunction (7%) patients. ORR CR 79% 62%, respectively. Seventeen (57%) underwent an HCT 8 (26%) Allogeneic (all haploidentical). follow up time from administration 12 months. Six died: = progression, non-relapse causes (Infection sepsis 2, GVHD=2). In addition this, one patient progressed soon another 22 months post HCT. Three year Overall survival (OS) Event free (EFS) probability post-BBv treatment 75% 58%, OS EFS analysis based on response (viz., CMR) demonstrated that CMR better [93% (p=0.0022) 3yr-OS 72% (p=0.038) 3yr-EFS probability].BBv active well-tolerated for HL, even settings. middle-income settings, cost constraints access uptake this regimen.